

You Lu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5490821/you-lu-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128
papers

2,771
citations

24
h-index

50
g-index

150
ext. papers

3,887
ext. citations

4.8
avg, IF

4.86
L-index

#	Paper	IF	Citations
128	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 990-8	21.7	291
127	Adeno-associated viruses undergo substantial evolution in primates during natural infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 6081-6	11.5	260
126	Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. <i>Nature Medicine</i> , 2000 , 6, 1160-5	56.5	208
125	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 867-875	8.9	141
124	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020 , 26, 732-740	50.5	138
123	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018 , 118, 654-661	8.7	121
122	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. <i>Lancet Respiratory Medicine, the</i> , 2019 , 7, 437-446	35.1	103
121	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4027-4034	2.2	97
120	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1539-1548	8.9	85
119	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pROgram by InnovENT anti-PD-1-11). <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1636-1646	8.9	75
118	Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E9640-E9648	11.5	69
117	PD-1/PD-L1 Inhibitors in Cervical Cancer. <i>Frontiers in Pharmacology</i> , 2019 , 10, 65	5.6	61
116	Ionizing Radiation-Induced Cellular Senescence in Normal, Non-transformed Cells and the Involved DNA Damage Response: A Mini Review. <i>Frontiers in Pharmacology</i> , 2018 , 9, 522	5.6	60
115	Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 74-87	4	56
114	Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. <i>Cancer Letters</i> , 2016 , 375, 349-359	9.9	56
113	Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. <i>Journal of Immunology</i> , 2003 , 170, 3162-70	5.3	54
112	Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019 , 13, 359-370	6.4	48

111	Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. <i>Oncotarget</i> , 2016 , 7, 57391-57413	3.3	45
110	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1907-1918	8.9	36
109	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017 , 13, 87-103	1.9	29
108	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. <i>Annals of Surgical Oncology</i> , 2019 , 26, 321-328	3.1	28
107	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. <i>Cancer Letters</i> , 2017 , 403, 186-194	9.9	25
106	Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 769-77	4	24
105	Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis. <i>Oncology Letters</i> , 2016 , 12, 1301-1314	2.6	24
104	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 401-7	5.9	23
103	Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. <i>Lung Cancer</i> , 2016 , 96, 93-100	5.9	21
102	Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. <i>Radiation Oncology</i> , 2014 , 9, 28	4.2	20
101	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1207-1217	2.2	17
100	Azithromycin attenuates acute radiation-induced lung injury in mice. <i>Oncology Letters</i> , 2017 , 14, 5211-5220		16
99	Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters. <i>Radiotherapy and Oncology</i> , 2019 , 132, 197-203	5.3	16
98	Ethyl pyruvate alleviates radiation-induced lung injury in mice. <i>Biomedicine and Pharmacotherapy</i> , 2017 , 92, 468-478	7.5	15
97	Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 212-224	4	15
96	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. <i>Oncotarget</i> , 2017 , 8, 49680-49688	3.3	15
95	Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer. <i>Radiation Oncology</i> , 2014 , 9, 117	4.2	14
94	Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2014 , 7, 260-266	2.6	14

93	Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells. <i>Cancer Letters</i> , 2015 , 365, 79-88	9.9	13
92	Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. <i>BMC Cancer</i> , 2016 , 16, 908	4.8	13
91	Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e59-e62	8.9	13
90	Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	13
89	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021 , 152, 7-14	5.9	13
88	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019 , 16, 189-204	5.2	12
87	Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e43-e45	8.9	12
86	Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 529-37	4	12
85	Postoperative chemoradiotherapy improves survival in patients with stage II-III esophageal squamous cell carcinoma: An analysis of clinical outcomes. <i>Thoracic Cancer</i> , 2016 , 7, 515-521	3.2	12
84	Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 127, 1-5	5.9	12
83	The association between TGF- β polymorphisms and radiation pneumonia in lung cancer patients treated with definitive radiotherapy: a meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e91100	3.7	11
82	Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score. <i>Oncotarget</i> , 2017 , 8, 111309-111317	3.3	11
81	Association between the interleukin-6 gene polymorphisms and renal cancer risk. <i>Immunology Letters</i> , 2015 , 164, 125-8	4.1	10
80	Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018 , 30, 147-156	3.8	10
79	MicroRNA Expression Profile on Solid Subtype of Invasive Lung Adenocarcinoma Reveals a Panel of Four miRNAs to Be Associated with Poor Prognosis in Chinese Patients. <i>Journal of Cancer</i> , 2016 , 7, 1610-1620	4.5	10
78	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2109-2120	8.9	10
77	Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019 , 1871, 323-330	11.2	9
76	PDGFR-inhibitor slows tumor growth but increases metastasis in combined radiotherapy and Endostar therapy. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 99, 615-621	7.5	9

75	Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 3269-3279	4.9	9
74	Synergy between peroxisome proliferator-activated receptor β agonist and radiotherapy in cancer. <i>Cancer Science</i> , 2018 , 109, 2243-2255	6.9	8
73	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.. <i>Lancet Oncology</i> , 2022 ,	21.7	8
72	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. <i>BMC Cancer</i> , 2015 , 15, 36	4.8	7
71	Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?. <i>Thoracic Cancer</i> , 2020 , 11, 631-639	3.2	7
70	FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients. <i>Cancer Biology and Therapy</i> , 2018 , 19, 76-86	4.6	7
69	The compound mutations in Chinese advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2019 , 20, 1097-1104	4.6	7
68	Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. <i>Strahlentherapie Und Onkologie</i> , 2020 , 196, 505-514	4.3	7
67	Expression analysis of the estrogen receptor target genes in renal cell carcinoma. <i>Molecular Medicine Reports</i> , 2015 , 11, 75-82	2.9	6
66	Phase 3 study of first-line crizotinib vs pemetrexed+displatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9058-9058	2.2	6
65	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 1349-1358	4	6
64	The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 1432-1441	4	6
63	The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model. <i>Inflammation</i> , 2017 , 40, 1254-1263	5.1	5
62	Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers. <i>CRISPR Journal</i> , 2018 , 1, 47-54	2.5	5
61	Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. <i>Oncotarget</i> , 2016 , 7, 66480-66490	3.3	5
60	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020 , 32, 448-466	3.8	5
59	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018 , 10, 816-824	2.6	5
58	Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study. <i>Thoracic Cancer</i> , 2013 , 4, 14-19	3.2	4

57	Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen. <i>Thoracic Cancer</i> , 2013 , 4, 234-240	3.2	4
56	Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC.. <i>Journal of the National Cancer Institute</i> , 2022 ,	9.7	4
55	Large-scale molecular epidemiological analysis of AAV in a cancer patient population. <i>Oncogene</i> , 2021 , 40, 3060-3071	9.2	4
54	Fluvastatin-mediated down-regulation of SATB1 affects aggressive phenotypes of human non-small-cell lung cancer cell line H292. <i>Life Sciences</i> , 2019 , 222, 212-220	6.8	4
53	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. <i>Journal of Thoracic Disease</i> , 2020 , 12, 639-650	2.6	4
52	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Exon 19 Deletion or L858R Mutations.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102641	2.2	4
51	Dosimetric effect of beam arrangement for intensity-modulated radiation therapy in the treatment of upper thoracic esophageal carcinoma. <i>Medical Dosimetry</i> , 2017 , 42, 47-52	1.3	3
50	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017 , 2, e000174	6	3
49	Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases. <i>OncoTargets and Therapy</i> , 2020 , 13, 647-656	4.4	3
48	Differential diagnosis of acute miliary pulmonary tuberculosis from widespread-metastatic cancer for postoperative lung cancer patients: two cases. <i>Journal of Thoracic Disease</i> , 2017 , 9, E115-E120	2.6	3
47	Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. <i>Frontiers in Oncology</i> , 2021 , 11, 739090	5.3	3
46	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. <i>Lung Cancer</i> , 2020 , 150, 240-246	5.9	3
45	The primary pulmonary NUT carcinomas and some uncommon somatic mutations identified by next-generation sequencing: a case report. <i>AME Case Reports</i> , 2020 , 4, 24	0.6	3
44	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , 2021 , 154, 176-185	5.9	3
43	Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis. <i>Clinical Lung Cancer</i> , 2021 , 22, e70-e83	4.9	3
42	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018 , 15, 5671-5679	2.6	2
41	Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014 , 2, 567-570	1.6	2
40	Salvage treatment with erlotinib after gefitinib failure in advanced non-small-cell lung cancer patients with poor performance status: A matched-pair case-control study. <i>Thoracic Cancer</i> , 2012 , 3, 27-33 ²		2

39	Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. <i>World Journal of Clinical Cases</i> , 2019 , 7, 1221-1229	1.6	2
38	Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	2
37	Alveolar rhabdomyosarcoma of nasopharynx and paranasal sinuses with metastasis to breast in a middle-aged woman: a case report and literature review. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 15316-21	1.4	2
36	Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report. <i>Annals of Translational Medicine</i> , 2019 , 7, 149	3.2	2
35	Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018 , 33, 421-426	3.9	2
34	KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.. <i>Nature Cancer</i> , 2022 ,	15.4	2
33	Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. <i>Journal of Comparative Effectiveness Research</i> , 2020 , 9, 93-102	2.1	1
32	Cancer screening education in Chinese medical schools. <i>Lancet Oncology, The</i> , 2014 , 15, e300-1	21.7	1
31	Targeting YAP acetylation in cancer. <i>Journal of Biological Chemistry</i> , 2012 , 287, 35442	5.4	1
30	Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20543-e20543	2.2	1
29	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9077-9077	2.2	1
28	Novel mutation in the gene in a Chinese boy with microcephaly and speech impairment: A case report. <i>World Journal of Clinical Cases</i> , 2020 , 8, 6465-6472	1.6	1
27	Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions. <i>Cancer Medicine</i> , 2020 , 9, 8772-8781	4.8	1
26	PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. <i>Scientific Reports</i> , 2020 , 10, 16150	4.9	1
25	Pseudo-small cell transformation in EGFR-mutant adenocarcinoma. <i>Lung Cancer</i> , 2021 , 153, 120-125	5.9	1
24	Development and validation of a nomogram for assessing survival in extensive-stage small-cell lung cancer patients with superior vena cava syndrome referred for thoracic radiotherapy: a comparison of upfront vs. consolidative approaches. <i>Strahlentherapie Und Onkologie</i> , 2021 , 197, 1072-1083	4.3	1
23	A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. <i>Investigational New Drugs</i> , 2020 , 38, 478-484	4.3	1
22	Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients. <i>Lung Cancer</i> , 2021 , 152, 104-108	5.9	1

21	Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?. <i>International Journal of Clinical Oncology</i> , 2018 , 23, 258-265	4.2	1
20	T790M mutation in stage IV EGFR-mutated NSCLC patient with acquired resistance reverted to original 19Del mutation after administration of a series of precision treatments: a case report. <i>Precision Clinical Medicine</i> , 2018 , 1, 129-133	6.7	1
19	Clinicopathologic Characteristics and Outcomes of Simultaneous Multiple Primary Lung Cancer.. <i>Journal of Oncology</i> , 2021 , 2021, 7722231	4.5	1
18	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.. <i>Lung Cancer</i> , 2021 , 165, 71-81	5.9	0
17	Marvelous objective response of low dose radiotherapy plus ICIs for extended stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21097-e21097	2.2	0
16	A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2021 , 1	4.3	0
15	Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced -Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100131	1.4	0
14	Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention (EMT-OCSP): a protocol for a pragmatic, multicentre, observer-blinded, 12-month randomised controlled study. <i>BMJ Open</i> , 2021 , 11, e043450	3	0
13	Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI. <i>Frontiers in Oncology</i> , 2020 , 10, 573512	5.3	0
12	Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie'S Disease: An Evidence-Based Analysis.. <i>Frontiers in Medicine</i> , 2022 , 9, 780956	4.9	0
11	Reply to A. Chalmers et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2341	2.2	
10	Negative pathology of ureteral carcinoma significantly delaying the diagnosis of the primary tumor of osteoblastic metastases: A case report and review of the literature. <i>Oncology Letters</i> , 2016 , 12, 2417-2420	2.6	
9	SNAILs promote G1 phase in selected cancer cells. <i>International Journal of Oncology</i> , 2015 , 47, 1863-73	4.4	
8	Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 2131-2136	2.2	
7	Phase I study of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small cell lung cancer patients with brain metastases: neurocognitive and quality-of-life analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20009-e20009	2.2	
6	Detect T790M in cell free tumor DNA of Chinese advanced non-small cell lung cancer adenocarcinoma patients by different platforms and evaluate clinical outcomes of T790M positive patients with osimertinib monotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS9104-TPS9104	2.2	
5	How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation? A bicenter research and pooled analysis of published reports.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20571-e20571	2.2	
4	Endostar plus gemcitabine/cisplatin (GP) with maintenance endostar as first-line therapy for advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18033-e18033	2.2	

- 3 Safety and efficacy of paclitaxel liposome monotherapy for the treatment of elderly patients with advanced non-small cell lung cancer: A prospective, multicenter, uncontrolled phase II study.. *Journal of Clinical Oncology*, **2012**, 30, e18086-e18086 2.2
- 2 Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.. *Journal of Clinical Oncology*, **2012**, 30, 4073-4073 2.2
- 1 Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study.. *Journal of Clinical Oncology*, **2021**, 39, e21131-e21131 2.2